Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07308574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 12 sitesv3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 26, 2025 to Dec 19, 2025 · Eligibility criteria revised · Site details revised at 12 of 12 sitesv2 Show 3 more changesShow less
    • Start date changed from estimate of Dec 26, 2025 to Dec 19, 2025
    • Eligibility criteria revised
    • Site details revised at 12 of 12 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Trial Details
NCT Number NCT07308574
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions aHUS, Atypical Hemolytic Uremic Syndrome
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov